STAT Plus: Pharmalittle: Novo launches plan to lower insulin costs; Sprout gets a win from FDA for female libido pill




And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is quite modest. We plan to catch up on our reading, hang with our shortest person, and do our best to gaze into the future. And what about you? Summer is not over, so perhaps a lazy drive to a beach or park is in order. Or you could get a head start on apple picking. Perhaps this is a good time to touch base with someone special or simply take stock of the world, such as it is. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

In the face of mounting criticism over insulin prices, Novo Nordisk (NVO) is mimicking its rivals by launching two programs that are designed to mitigate rising costs for patients, STAT reports. The two-pronged effort involves a $99 cash card that can be used by anyone — regardless of whether they have insurance coverage — for a month’s supply and the introduction of authorized generic versions of two different insulin products at half the list price. These will be identical to the Novolog and Novolog Mix brand-name treatments.

Continue to STAT Plus to read the full story…



Source link

Leave a Reply!

So glad to see you sticking around!

Want to be the first one to receive the new stuff?

Enter your email address below and we'll send you the goodies straight to your inbox.

Thank You For Subscribing!

This means the world to me!

Spamming is not included! Pinky promise.